BioLife Solutions to Supply CryoStor™ to Cryobanks International
News Nov 12, 2008
BioLife Solutions, Inc. has announced that it will supply its CryoStor biopreservative freezing media to Cryobanks International, a Florida-based cord blood stem cell bank for private and public-donation purposes, for long-term storage of stem cells isolated from umbilical cord blood.
Umbilical cord blood, which is typically discarded after birth, is a rich source of stem cells that have been transfused in thousands of patients to cure numerous fatal diseases including leukemia, lymphoma, anemia, and myelofibrosis.
Cryobanks Chief Operating Officer Robert Gravely stated: “We are an AABB (formerly American Association of Blood Banks) accredited participating member of the National Marrow Donor Program and currently have more than ten thousand cord blood units available for unrelated recipients.
“We strive to continually improve the quality and effectiveness of our biopreservation systems,” Gravely continued, “and BioLife’s scientific data indicated that the use of pre-formulated CryoStor as the freezing media resulted in improved post-preservation stem cell viability and function. After conducting further evaluations of CryoStor, we decided to replace our internally formulated media with CryoStor, which is produced under current Good Manufacturing Practices (cGMP) and supported by a Master File with the U.S. Food and Drug Administration (FDA).”
BioLife Chief Executive Mike Rice commented: “Cryobanks’ decision to adopt CryoStor as their standard cord blood biopreservative freezing media represents further confirmation of the value that our products bring to customers in the form of manufacturing and ingredient quality, measurably superior results, and ease of use. We’re pleased to supply CryoStor to Cryobanks to support the growth of their business and will continue to expand our customer base and broaden adoption of CryoStor and HypoThermosol as the worldwide standard for media to transport, preserve and store cells, tissues, and organs.”
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE